52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Trial details
- Registry ID
- NCT06689085
- Drugs studied
- Testosterone enanthate
TrialRedline tracks 1 clinical trial sponsored by Halozyme Therapeutics: 1 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismNCT06689085 | Testosterone enanthate | Recruiting | 2028-03Estimated |
Names as written in the registry records.
Before: Oct 2027. After: Mar 2028.